Antiparkinsonian Effects of BAM‐1110, a Novel Ergoline Derivative, in MPTP‐Treated Cynomolgus Monkeys
作者:
Sadako Kuno,
Eiji Mizuta,
Hirohiko Sakamoto,
Kenji Ichihara,
Mitsuaki Nagasaka,
期刊:
Clinical Neuropharmacology
(OVID Available online 1998)
卷期:
Volume 21,
issue 1
页码: 35-40
ISSN:0362-5664
年代: 1998
出版商: OVID
关键词: BAM-1110;Antiparkinsonian drug;Dopamine agonist;MPTP-treated cynomolgus monkey.
数据来源: OVID
摘要:
BAM-1110 [(5R,8R,10R)-6-methyl–8–(1,2,4-triazol-l-ylmethyl) ergoline maleate] is a newly synthesized dopamine agonist that produces little anorexic side effects (nausea and vomiting). The current study examines the effects of BAM-1110 on parkinsonian symptoms in l-methyl–4–phenyl-l,2,3,6-tetrahydropyridine (MPTP)-treated monkeys, an animal model of Parkinson's disease. First, a significant antiparkinsonian effect of apomorphine hydrochloride (0.3 mg/kg given subcutaneously) was confirmed in these animals. BAM-1110 (0.1, 0.3, and 1 mg/kg subcutaneously) relieved parkinsonian symptoms in a dose-dependent manner. Significant effects were observed at doses of 0.3 and 1 mg/kg and lasted for at least 3 h. BAM-1110, at a dose of 0.3 mg/kg that produced the submaximal antiparkinsonian effect, did not induce significant abnormal behaviors such as hyperactivity and stereotyped behaviors. Significant stereotyped behaviors were observed at 1 mg/kg of BAM-1110. Apomorphine induced hyperactive and stereotyped behaviors in parallel with its antiparkinsonian effect. BAM-1110 appears to be a potentially useful dopamine agonist to treat Parkinson's disease because of its relatively weak drug-induced hyperactive disturbances and anorexic side effects.
点击下载:
PDF
(405KB)
返 回